Equities
Health CarePharmaceuticals & Biotechnology
  • Price (USD)86.57
  • Today's Change-0.91 / -1.04%
  • Shares traded8.29m
  • 1 Year change33.23%
  • Beta1.5042
Data delayed at least 15 minutes, as of Sep 25 2017 21:00 BST.
More ▼

Key statistics

On Monday, AbbVie Inc (ABBV:NYQ) closed at 86.57, -3.48% below its 52-week high of 89.69, set on Sep 15, 2017.
52-week range
Today
55.06Oct 28 201689.69Sep 15 2017
Markit short selling activity
Low
Med
High
Open86.92
High87.78
Low86.40
Bid86.00
Offer87.00
Previous close87.48
Average volume10.00m
Shares outstanding1.59bn
Free float1.59bn
P/E (TTM)21.36
Market cap139.45bn USD
EPS (TTM)4.09
USD
Annual div (ADY)2.56
USD
Annual div yield (ADY)2.93%
Div ex-dateJul 12 2017
Div pay-dateAug 15 2017
Next div ex-dateOct 12 2017
Next div pay-dateNov 15 2017
Data delayed at least 15 minutes, as of Sep 25 2017 21:00 BST.
More ▼

Investors Chronicle View

The last IC recommendation on AbbVie Inc shares was Hold at 4,801.00 on 16 Jul 2014Read the full article
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.